Risperidone (depot) for schizophrenia

Sampson, Stephanie; Hosalli, Prakash; Furtado, Vivek; Davis, John M.

doi:10.1002/14651858.cd004161.pub2

Cited by 22 publications

(13 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 177 studies with 58,069 participants across 414 treatment arms were included in the comparative analysis (Appendix ) 32–111 . Of these, the breakdown for numbers of studies including each medication are aripiprazole (88), asenapine (10), brexpiprazole (8), cariprazine (10), iloperidone (6), lurasidone (14), paliperidone (9), risperidone (25), and ziprasidone (11).…”

Section: Resultsmentioning

confidence: 99%

Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence

et al. 2020

View full text Add to dashboard Cite

Akathisia continues to present a significant challenge in clinical practice. As a class, so-called atypical, or second-generation, antipsychotics (SGAs) are the mainstay of treatment for schizophrenia and are commonly used to treat mood disorders. These medications have traditionally been distinguished from first-generation antipsychotics by their lowered risk of extrapyramidal side effects (EPS) such as dystonia, dyskinesia, akathisia, and pseudoparkinsonism. However, the occurrence of EPS, particularly akathisia, has been demonstrated to some degree in all commercially available SGAs. This review examines the incidence of akathisia in nine newer SGAs in patients with schizophrenia, bipolar disorder, and major depressive disorder (MDD). We performed a search of PubMed, ClinicalTrials.gov, Cochrane Central Register, and Google Scholar, as well as manufacturer websites and product labeling for published and unpublished clinical trials, meta-analyses, and systematic reviews. Studies evaluating adult patients with schizophrenia, bipolar disorder, or MDD were eligible for inclusion. Data on treatment-emergent akathisia rates were gathered from each study, and potential dose-response relationships were explored. A total of 177 studies were included in this review, comprising 58,069 patients across 414 treatment arms. Compared with placebo with a composite 3.7% incidence of akathisia, individual SGAs produced akathisia at total composite rates ranging from 2.9-13.0% across the included studies. High doses of an SGA were generally associated with an increased risk of akathisia. Clinicians should consider the risk of akathisia when choosing a treatment option and monitor for akathisia in patients beginning therapy with an SGA or following a dose increase of the SGA. KEY WORDS akathisia, antipsychotics, bipolar disorder, major depressive disorder, schizophrenia. (Pharmacotherapy 2020;40(6):565-574)

show abstract

Section: Resultsmentioning

confidence: 99%

Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 1 Its symptoms are generally divided into positive forms (eg, hallucinations, delusions, and disorganized behaviors) and negative forms (eg, anhedonia, alogia, and apathy). 2 – 4 Risperidone, 5 the most commonly prescribed antipsychotic in China, 6 has been reported to be desirable for treating both positive and negative symptoms of schizophrenia. 7 Also risperidone was effective and generally well tolerated in Chinese patients.…”

Section: Introductionmentioning

confidence: 99%

Potential link between genetic polymorphisms of <em>catechol-O-methyltransferase </em>and dopamine receptors and treatment efficacy of risperidone on schizophrenia

Wang²

2017

NDT

View full text Add to dashboard Cite

ObjectiveThe current study aimed to explore the association of single nucleotide polymorphisms (SNPs) within catechol-O-methyltransferase (COMT) and dopamine receptors with schizophrenia and genetic association with risperidone treatment response.MethodsA total of 690 schizophrenic patients (case group) were selected and 430 healthy people were included as the controls. All patients received risperidone treatment continuously for 8 weeks. Next, peripheral venous blood samples were collected and were subjected to polymerase chain reaction-restriction fragment length polymorphism to amplify and genotype the SNPs within COMT and dopamine receptors. Then, correlation analysis was conducted between Positive and Negative Syndrome Scale improvement rates and SNPs within COMT and the dopamine receptor gene.ResultsThe allele of DRD1 rs11749676 (A) emerged as a key element in reducing schizophrenia risk with statistical significance (P<0.001). Remarkably, alleles of COMT rs165774 (G), DRD2 rs6277 (T), and DRD3 rs6280 (C) were associated with raised predisposition to schizophrenia (all P<0.001). Regarding DRD1 rs11746641, DRD1 rs11749676, DRD2 rs6277, and DRD3 rs6280, the case group exhibited a lesser frequency of heterozygotes in comparison with wild homozygotes genotype (all P<0.001). SNPs (COMT rs4680, DRD2 rs6275, DRD2 rs1801028, and DRD2 rs6277) were remarkably associated with improvement rates of PANSS total scores (P<0.05). SNPs (COMT rs165599 and DRD2 rs1801028) were significantly associated with risperidone efficacy on negative symptoms (P<0.05).ConclusionCOMT SNPs and dopamine receptor SNPs were correlated with prevalence of schizophrenia and risperidone treatment efficacy of schizophrenia.

show abstract

“…Our systematic search of the Cochrane Database of Systematic Reviews yielded a total of 37 Cochrane systematic reviews (28 for SGAs), 15 –50 which generated 316 informative randomised controlled trials (243 for SGAs). Most of these studies did not include children or adolescents; 0% to 5% of studies included patients below 18 years of age, of which fewer than 10% were below the age of 18 years.…”

Section: Resultsmentioning

confidence: 99%

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D R association rate and serotonin 5-HT antagonism, could contribute to this variation.

show abstract

Risperidone (depot) for schizophrenia

Cited by 22 publications

References 80 publications

Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence

Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence

Potential link between genetic polymorphisms of <em>catechol-O-methyltransferase </em>and dopamine receptors and treatment efficacy of risperidone on schizophrenia

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

Contact Info

Product

Resources

About